Abstract:AIM:Point mutation, one of the commonest gene mutations, is the most important molecular pathogenesis of cancer and chronic infection. The commonest methods for detection of point mutation are based on polymerase chain reaction (PCR). These techniques, however, cannot be used in large scale screening since they are neither accurate nor simple. For this reason, this study established a novel method of competitively differentiated PCR (CD-PCR) for screening point mutation in clinical practice.METHODS:Two competitively differentiated primers for mutant-type and wild-type templates respectively with an identically complemented region in 3' end except for last 2 base pairs and a different non-complemented region in 5' end were designed. Thus, competitive amplification might be carried out at a lower annealing temperature at first, and then differentiated amplification at a higher annealing temperature when primers could not combine with initial templates. The amplification was performed in one-tube. The products of CD-PCR were detected using microplate hybridization assay. CD-PCR was evaluated by detecting G1896A variant of hepatitis B virus (HBV) in form of recombinant plasmids and in sera from patients with hepatitis B, and compared with allele-specific PCR (AS-PCR) and competitive AS-PCR.RESULTS:CD-PCR was successfully established. It could clearly distinguish wild-type and mutant-type plasmid DNA of G1896A variant when the amount of plasmid DNA was between 10(2)-10(8)copies/reaction, while for AS-PCR and competitive AS-PCR, the DNA amount was between 10(2)-10(4)copies/reaction. CD-PCR could detect one copy of G1896A variant among 10-100 copies of wild-type plasmid DNA. The specificity of CD-PCR was higher than those of AS-PCR and competitive AS-PCR in the detection of HBV G1896A variant in sera from patients with hepatitis B. CD-PCR was independent of the amount of HBV DNA in serum. HBV G1896A variant was more often found in HBeAg (-) patients with a lower level of detectable viremia than that with a higher level of detectable viremia (P=0.0192).CONCLUSION:CD-PCR is more specific since it is less influenced by the amount of initial templates and the cross amplification between mutant- and wild-type amplified products. It is also simple and time-saving. Thus, CD-PCR might be useful in routine gene typing and point mutation screening. HBV G1896A or other more important mutations have to be routinely detected in patients with a detectable level of viremia after HBeAg/antibody conversion in clinical practice.

Determination of PCR Product by Bioluminescence

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

Quantification of TT Virus DNA by fluorescence real time PCR and Its clinical significance

Evaluation of Nucleic Acid Extraction Methods on HBV DNA Detection by Fluorescence Quantitative PCR (Taqman)

The Measurement of HBV DNA in peripheral blood mononuclear cells and its clinical applicability

Detection of Bacterial DNA by Polymerase Chain Reaction and Reverse Hybr Idization of 16srrna Gene

Real-Time PCR Assay Using Molecular Beacon for Quantitation of Hepatitis B Virus DNA

Establishment and Application of a Real-Time PCR Method to Detect Hepatitis B Virus Cccdna Quantitatively

A New and Sensitive Method for the Quantification of HBV Cccdna by Real-Time PCR

Determination of HCV RNA concentration by direct quantitation of the products from a single RT-PCR

Evaluation of a Novel Fully Automated Real-Time PCR Assay for Hepatitis B Virus DNA Quantification

Evaluation for Quantitative Methods of HBV DNA in Serum with Very High Viral Loads

Multiplex Locked Nucleic Acid Probes for Analysis of Hepatitis B Virus Mutants Using Real-Time PCR

Sequence-encoded Quantitative Invader Assay Enables Highly Sensitive Hepatitis B Virus DNA Quantification in a Single Tube Without the Use of a Calibration Curve.

Analysis of Genotype and Quantification of Hepatitis B Virus by Real-Time PCR Assay

Real-time Quantitative Detection of Sera HBV DNA in Parients with Hepatitis B and Its Clinical Application

Evaluation of a novel domestic hepatitis B viral DNA quantitative fluorescence diagnostic kit

[Detection of the HBV DNA with Sybr Green 1 Realtime Polymerase Chain Reaction].

Novel Assay of Competitively Differentiated Polymerase Chain Reaction for Screening Point Mutation of Hepatitis B Virus.

Agarose-Droplet-Based Digital LAMP Assay for Counting Virus DNA in Single-Particle ICP-MS

The Clinical Significance of Up-Converting Phosphor Immunochromatography in Detecting Hepatitis B Virus Large Envelope Protein in Various Types of Chronic Liver Disease